Brief: Cantargia Broadens Development Of nadunolimab, Submits Application For Clinical Trial CESTAFOUR

Cantargia AB

29/06/2021 13:07

June 29 (Reuters) - Cantargia AB  CANTA.ST :
    * CANTARGIA BROADENS THE DEVELOPMENT OF NADUNOLIMAB IN THREE
FORMS
OF CANCER AND SUBMITS APPLICATION FOR THE PHASE I/II CLINICAL
TRIAL CESTAFOUR
    * DEVELOPMENT OF NADUNOLIMAB (CAN04) HAS BEEN BROADENED
FOLLOWING
SUBMISSION OF AN APPLICATION OF A PHASE I/II CLINICAL TRIAL TO
EVALUATE COMBINATION WITH CHEMOTHERAPY IN THREE DIFFERENT FORMS
OF SOLID TUMORS
    * STUDY, CALLED CESTAFOUR, WILL BE CONDUCTED AT
APPROXIMATELY 20
CLINICAL CENTRES IN EUROPE
    * CLINICAL TRIAL APPLICATION FOR A FOURTH STUDY, CALLED
CESTAFOUR,
HAS NOW BEEN SUBMITTED

Source text for Eikon:  ID:nWkr2w3LqJ 
Further company coverage:  CANTA.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))